Security key
68403P203
ORAMED PHARMACEUTICALS INC. - Common Stock (ORMP)
CUSIP: 68403P203
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 7,251,222
- Total 13F value
- $16,313,647
- Share change
- -520,565
- Put/Call ratio
- 0%
- SEC-reported price per share
- $2.25
- Number of holders
- 47
- Value change
- -$1,132,788
- Number of buys
- 11
- Number of sells
- 25
- Shares outstanding
- 40,467,431
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
47
Top holders
10
ORMP full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Previous quarter: Q1 2025
ORAMED PHARMACEUTICALS INC. SEC filings
ORAMED PHARMACEUTICALS INC. company facts
ORAMED PHARMACEUTICALS INC. 13D/G history
Broader feeds
Reporting periods
Holder history for CUSIP 68403P203
Recent filing periods:
Ownership snapshot
Top reported holders of ORMP - ORAMED PHARMACEUTICALS INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Nadav Kidron
Disclosed value leader
Nadav Kidron
Comparable rows
15/15
Latest evidence
05 Jun 2025
13D/G
3/4/5
13F
Lead comparable stake: 7.6%
13D/G row: Nadav Kidron
Showing 1-6 of 15 holder rows.
Quick read
Nadav Kidron leads the comparable SEC ownership view at 7.6%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Nadav Kidron's linked filing trail.
Comparable ownership
Top 5
Nadav Kidron
7.6%
Leonard Sank
0.33%
BML Capital Management, LLC
7.5%
Murchinson Ltd.
4.3%
BOOTHBAY FUND MANAGEMENT, LLC
2.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Nadav Kidron |
13D/G
|
7.6%
|
$6,638,633
3,116,729 shares
|
$0 | 11 Feb 2025 |
| Leonard Sank |
3/4/5
Director
|
0.33%
|
$301,349
134,531 shares
|
— | 05 Jun 2025 |
| BML Capital Management, LLC |
13F
Company
|
7.5%
|
$6,464,401
3,020,748 shares
|
— | 31 Mar 2025 |
| Murchinson Ltd. |
13F
Company
|
4.3%
|
$3,748,764
1,751,759 shares
|
— | 31 Mar 2025 |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
Company
|
2.1%
|
$1,809,344
845,488 shares
|
— | 31 Mar 2025 |
| Peapod Lane Capital LLC |
13F
Company
|
0.62%
|
$539,759
252,224 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
47
Shares
7,251,222
Rows available
47
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
52
Q2 2025 holders
47
Holder diff
-5
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend